AIDS Interview | Doxycycline Pre-Exposure Prophylaxis Shows Significant Effects in Preventing STIs Among HIV-Positive Individuals

AIDS Interview | Doxycycline Pre-Exposure Prophylaxis Shows Significant Effects in Preventing STIs Among HIV-Positive Individuals

At the 25th International AIDS Conference, a study led by Dr. Troy Grennan from the British Columbia University and the Canadian Centre for Disease Control revealed the astonishing effectiveness of doxycycline pre-exposure prophylaxis (DoxyPrEP) in reducing the incidence of bacterial sexually transmitted infections (STIs) among HIV-positive men who have sex with men. The study found that taking 100 mg of doxycycline daily significantly reduced the incidence of syphilis, chlamydia infection, and gonorrhea, with an overall reduction rate of up to 80%. This breakthrough discovery not only provides a new strategy for STI prevention but also offers important evidence for future public health policy formulation. With the advancement of larger-scale clinical trials, doxycycline is expected to become an important tool in the field of STI prevention, contributing to global public health security. " Infectious Disease Frontier"（IIDF） invited Dr. Troy Grennan for an exclusive interview.
Dr. Mark Muthiah: Exploration of Liver Fibrosis Reversal and Patient Clinical Management

Dr. Mark Muthiah: Exploration of Liver Fibrosis Reversal and Patient Clinical Management

Recently, the Combined GlHep&SHC 2024 was held in Singapore. This conference brings together elite scholars in the field of liver disease from around the world to discuss the latest developments, challenges, and opportunities in liver disease. Hepatology Digest invited Dr. Mark Muthiah from the National University Hospital, Singapore to conduct in-depth discussions on issues related to liver fibrosis and patient clinical management. The following is a transcript of the interview.
Dr Ken Liu: New Technology for Hepatocellular Carcinoma Detection

Dr Ken Liu: New Technology for Hepatocellular Carcinoma Detection

The Combined GlHep&SHC 2024 was recently held in Singapore. This conference brings together elite scholars in the field of liver disease from around the world to discuss the latest developments, challenges, and opportunities in liver disease. Liver cancer is the third leading cause of cancer death worldwide, and hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for 90% of all liver cancers. During the conference, our magazine invited Dr Ken Liu from the Royal Prince Alfred Hospital in Australia to conduct an exclusive interview on HCC related issues.
International Lung Cancer Conferenc | Dr. Huijuan Wang Reviews Perioperative Treatment Advances in NSCLC

International Lung Cancer Conferenc | Dr. Huijuan Wang Reviews Perioperative Treatment Advances in NSCLC

The perioperative treatment of early-stage non-small cell lung cancer (NSCLC) has now entered the era of precision-targeted therapy and immunotherapy. At the NSCLC Medical Treatment Session of the International Lung Cancer Conference (CLC 2024) held from August 9-11, Dr. Huijuan Wang from Henan Cancer Hospital delivered a keynote speech titled "Advances in Perioperative Treatment of NSCLC." This article provides a brief overview of the content of her presentation.
International Lung Cancer Conference | Dr. Panwen Tian: Exploration and Practice of Biomarkers in Lung Cancer Immunotherapy

International Lung Cancer Conference | Dr. Panwen Tian: Exploration and Practice of Biomarkers in Lung Cancer Immunotherapy

The exploration of biomarkers in immunotherapy is constantly evolving, yet only a few have proven to effectively guide clinical decision-making. At the 2024 International Lung Cancer Conference (CLC 2024), held from August 9-11, Dr. Panwen Tian from West China Hospital of Sichuan University delivered a keynote speech titled "Thoughts and Exploration of Biomarkers in Lung Cancer Immunotherapy." This article provides a brief overview of the report.
2024 COMB丨Dr. Tao Sun: Advancements in HER2+ EBC Treatment—De-escalation Therapy and the Future of ctDNA Applications

2024 COMB丨Dr. Tao Sun: Advancements in HER2+ EBC Treatment—De-escalation Therapy and the Future of ctDNA Applications

In recent years, the field of breast cancer treatment has witnessed a series of innovative research developments, particularly in the treatment of HER2+ early breast cancer (EBC). Strategies such as "de-escalation," "chemotherapy-free," and "precision treatment" have become hot topics. At the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (2024 COMB), Oncology Frontier invited Dr. Tao Sun from Liaoning Cancer Hospital to delve into the latest developments and future directions in the treatment of HER2+ EBC.
2024 COMB丨Dr. Jiani Wang: Insights on the ADAPT Study and New Advances in Precision Treatment for HER2+ Breast Cancer

2024 COMB丨Dr. Jiani Wang: Insights on the ADAPT Study and New Advances in Precision Treatment for HER2+ Breast Cancer

At the full-session management segment of the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (2024 COMB), Dr. Jiani Wang from the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, along with three other breast cancer experts, engaged in a deep discussion on the significance of the ADAPT study for HER2+ breast cancer treatment and how to manage patients throughout the treatment process. Following the conference, Oncology Frontier invited Dr. Jiani Wang to provide an in-depth analysis of the ADAPT study. She also shared the latest achievements of her team in the field of anti-HER2 treatment and her expectations for the treatment of HER2-positive breast cancer patients.
Dr Vincent Wong: Lean metabolic associated fatty liver disease from a clinical perspective

Dr Vincent Wong: Lean metabolic associated fatty liver disease from a clinical perspective

The Combined GlHep&SHC 2024 will be held in Singapore from July 25th to 28th, 2024. This conference brings together elite scholars in the field of liver disease from around the world to discuss the latest developments, challenges, and opportunities in liver disease. Hepatology Digest invited Dr Vincent Wong from The Chinese University of Hong Kong to conduct in-depth discussions on the epidemiology of metabolic associated fatty liver disease (MAFLD), lean MAFLD, and other related issues.
Dr Lim Seng Gee: Looking forward to the emergence of new treatment methods for MAFLD in the future

Dr Lim Seng Gee: Looking forward to the emergence of new treatment methods for MAFLD in the future

Recently, the Combined GlHep&SHC 2024 was held in Singapore. This conference covers various aspects of liver disease research and provides an interdisciplinary communication platform for experts and scholars. During the conference, Hepatology Digest conducted an exclusive interview with Professor Lim Seng Gee from the National University Hospital of Singapore, asking him to introduce the current status of liver disease in Singapore, metabolic associated fatty liver disease (MAFLD), and other related topics.